According to the U.S. FDA, a higher initial dose of the monoclonal antibody treatment tixagevimab-cilgavimab may be required to prevent cases of Omicron subvariants, BA.1 and BA.1.1.

FDA revised the emergency use authorization (EUA) for the antibody combination and increased the initial dosing regimen from a 150 mg injection of each drug to a 300 mg injection of each drug. The treatment is indicated as pre-exposure prophylaxis for people aged 12 years and above who are either moderately or severely immunocompromised and may not develop an adequate response to COVID-19 vaccination, or people who are allergic to some vaccine components. The agency stated that patients who have already received the 150 mg doses should be given the additional 150 mg doses of each drug at the earliest… (Medpage Today)